Nurami Medical finishes recruitment for tissue damage clinical trial

Nurami Medical's new product – ArtiFascia – is a synthetic implant for restoring and repairing membranes after surgical procedures.

From left: Nurami co-founder Nora Nseir Manassa, PlasFree Operations Manager Samah Waked and PlasFree R&D manager Dr. Nuha Higazi (photo credit: Courtesy)
From left: Nurami co-founder Nora Nseir Manassa, PlasFree Operations Manager Samah Waked and PlasFree R&D manager Dr. Nuha Higazi
(photo credit: Courtesy)

Israeli medical company Nurami Medical announced on Thursday that it has filled 100% of its spots for an upcoming clinical trial.

Nurami, which was founded by Nora Nseir and Dr. Amir Bahar, has developed innovative technology for repairing soft tissue and speeding up the recovery process after surgical procedures. The company will test its inaugural product – ArtiFascia, which restores and repairs tissue damaged during surgical procedures – for regulatory approval by the FDA (for the US market) and the CE (for the EU market).

The clinical trial is expected to be completed after six months of monitoring all the patients, with the results expected several months afterward.

The ArtiFascia is a synthetic implant for restoring and repairing membranes after surgical procedures. It is based on friendly materials that encourage the healing of damaged tissues, and further combines the ability to fully seal against the entry of infections and the leakage of bodily fluids.

 Hanoch Markshade, CEO of Nurami ​​Medical. (credit: NURAMI MEDICAL) Hanoch Markshade, CEO of Nurami ​​Medical. (credit: NURAMI MEDICAL)

Nurami is also developing solutions and products for healing and repairing other soft tissues in the body.

The company has raised about $11 million to date from the Israel Innovation Authority and other investors, including the NGT3 venture capital fund and investors from China.